Cholesterol Self-testing in Patients Post Acute Coronary Syndrome
University of Leipzig
200 participants
Jun 1, 2024
INTERVENTIONAL
Conditions
Summary
The pharmacological reduction of LDL-C lowers cardiovascular risk and is therefore a priority in cardiovascular secondary prevention. The achievement of LDL-C target levels in Germany, Europe, and worldwide is inadequate, despite a wide array of lipid-lowering medications. Only a small proportion of post-myocardial infarction patients reach their LDL-C target range within a year. There is a significant need for new strategies to improve LDL-C target achievement and thereby reduce the occurrence of secondary cardiovascular events. The aim of the study is to establish a basis for improving prevention by achieving the target LDL level effectively and quickly in patients with high and very high cardiovascular risk profiles.
Eligibility
Inclusion Criteria3
- Age ≥ 18 years
- Patients with acute coronary syndrome in the last 6 months and not having reached the LDL target value
- Signed informed consent
Exclusion Criteria6
- Persons unable to understand the study
- Persons unable or unwilling to perform self-measurements
- Persons unable or unwilling to undergo additional cholesterol-lowering therapy to reach the LDL target
- Pre-menopausal women without contraception
- Use of experimental drugs or investigational products within 30 days prior to screening
- Employees or contractors of the institution conducting the study or family members of the Principal Investigator, Co-Investigator, or financial supporter
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will be trained to use a device to self-measurement of cholesterol-values monthly. After the measurement they will report their results to study team for ajusting the therapy.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06526013